北京大学学报(医学版) ›› 2014, Vol. 46 ›› Issue (4): 653-656.

• 病例报告 • 上一篇    下一篇

醋酸阿比特龙治疗3例未化疗有骨转移去势抵抗性前列腺癌

马宏,朱刚,万奔△,吴鹏杰,王建业   

  1. (卫生部北京医院泌尿外科,北京100730)
  • 出版日期:2014-08-18 发布日期:2014-08-18

Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review

MA Hong, ZHU Gang, WAN Ben△, WU Peng-jie, WANG Jian-ye   

  1. (Department of Urology, Beijing Hospital of the Ministry of Health, Beijing 100730, China)
  • Online:2014-08-18 Published:2014-08-18

关键词: 肿瘤, 激素依赖性, 前列腺肿瘤, 阿比特龙

Abstract: Objective:To evaluate the safety and efficiency of using abiraterone and prednisone in the treatment of patient with metastatic castration resistant prostate cancer (mCRPC) no prior chemotherapy. Methods: Three mCRPC no prior chemotherapy patients accepted abiraterone and prednisone treatment. The clinical data were analyzed retrospectively and the safety and efficiency of this treatment option were discussed. The Gleason scores of the three mCRPC patients were 5, 9, and 9. The clinical stages were T3aNxM0, T3aNxM1b, and T3aNxM1b. The patients received abiraterone 1 000 mg daily and prednisone 5 mg twice daily and androgen deprivation therapy in the treatment. Their blood pressure, complete blood count, prostate specific antigen (PSA), biochemical parameters, whole body CT scan and bone scan were done regularly to monitor the progression of the diseases. Results: In this study, the general condition improved in two patients. Two of the three patients experienced decrease of PSA and no progression. One patient experienced disease progression. Generally, abiraterone and prednisone resulted in prolonged radiographic progression-free survival and delayed in PSA progression in mCRPC no prior chemotherapy. There were no severe side effects, such as hypokalemia, hypertension, and water-sodium retention. The patient’s tolerance was good. Conclusion:Abiraterone and prednisone are safe and can improve mCRPC no prior chemotherapy patient’s life quality and may prolong the overall survival.

Key words: Neoplasms, hormone-dependent, Prostatic neoplasms, Abiraterone

[1] 黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报(医学版), 2024, 56(4): 557-561.
[2] 田宇轩,阮明健,刘毅,李德润,吴静云,沈棋,范宇,金杰. 双参数MRI改良PI-RADS评分4分和5分病灶的最大径对临床有意义前列腺癌的预测效果[J]. 北京大学学报(医学版), 2024, 56(4): 567-574.
[3] 姚凯烽,阮明健,李德润,田宇轩,陈宇珂,范宇,刘毅. 靶向穿刺联合区域系统穿刺对PI-RADS 4~5分患者的前列腺癌诊断效能[J]. 北京大学学报(医学版), 2024, 56(4): 575-581.
[4] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报(医学版), 2024, 56(4): 582-588.
[5] 王滨帅,邱敏,张前进,田茂锋,刘磊,王国良,陆敏,田晓军,张树栋. 6例肾尤文肉瘤伴静脉瘤栓的诊治[J]. 北京大学学报(医学版), 2024, 56(4): 636-639.
[6] 虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报(医学版), 2024, 56(4): 661-666.
[7] 舒帆,郝一昌,张展奕,邓绍晖,张洪宪,刘磊,王国良,田晓军,赵磊,马潞林,张树栋. 肾部分切除术治疗囊性肾癌的功能学和肿瘤学结果:单中心回顾性研究[J]. 北京大学学报(医学版), 2024, 56(4): 667-672.
[8] 方杨毅,李强,黄志高,陆敏,洪锴,张树栋. 睾丸鞘膜高分化乳头状间皮肿瘤1例[J]. 北京大学学报(医学版), 2024, 56(4): 741-744.
[9] 柴晓东,孙子文,李海爽,朱靓怡,刘小旦,刘延涛,裴斐,常青. 髓母细胞瘤分子亚型中CD8+T淋巴细胞浸润的临床病理特点[J]. 北京大学学报(医学版), 2024, 56(3): 512-518.
[10] 林国中,马长城,吴超,司雨,杨军. 微通道技术在颈椎管肿瘤微创切除术中的应用[J]. 北京大学学报(医学版), 2024, 56(2): 318-321.
[11] 俞光岩. 儿童唾液腺疾病[J]. 北京大学学报(医学版), 2024, 56(1): 1-3.
[12] 王薇,王佳宁,虞巍,朱赛楠,高莹,张俊清. 肾上腺性库欣综合征与无功能腺瘤患者的凝血功能比较及其影响因素[J]. 北京大学学报(医学版), 2023, 55(6): 1062-1067.
[13] 薛蔚,董樑,钱宏阳,费笑晨. 前列腺癌新辅助治疗与辅助治疗的现状及进展[J]. 北京大学学报(医学版), 2023, 55(5): 775-780.
[14] 薛子璇,唐世英,邱敏,刘承,田晓军,陆敏,董靖晗,马潞林,张树栋. 青年肾肿瘤伴瘤栓的临床病理特征及预后分析[J]. 北京大学学报(医学版), 2023, 55(5): 802-811.
[15] 刘毅,袁昌巍,吴静云,沈棋,肖江喜,赵峥,王霄英,李学松,何志嵩,周利群. 靶向穿刺+6针系统穿刺对PI-RADS 5分患者的前列腺癌诊断效能[J]. 北京大学学报(医学版), 2023, 55(5): 812-817.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!